Copyright © 2001 by the European Society of Cardiology.
Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy
a Department of Cardiology and Cardiac Surgery, ‘Federico II’ University School of Medicine, Naples, Italy
b Department of Experimental Medicine and Pathology, ‘La Sapienza’ University School of Medicine, Rome, Italy
c IRCCS Neuromed, Pozzilli (IS), Italy
revised September 26, 2000; accepted October 11, 2000
Abstract
Aims Atrial and brain natriuretic peptide levels closely reflect impaired left ventricular function in patients with heart failure. In the present study we assessed the determinants and the clinical significance of atrial and brain natriuretic peptide plasma levels in hypertrophic cardiomyopathy.
Methods and Results In 44 patients with hypertrophic cardiomyopathy (40±15 years) we evaluated: (a) atrial and brain natriuretic peptide plasma levels; (b) left ventricular hypertrophy; (c) left ventricular ejection fraction; (d) transmitral and pulmonary venous flow velocity patterns, and left atrial fractional shortening; (e) left ventricular outflow tract gradient; (f) maximal oxygen consumption. Left ventricular hypertrophy influenced only brain natriuretic peptide levels (r=0·32;P<0·05). Atrial and brain natriuretic peptide plasma levels did not correlate with left ventricular ejection fraction, but correlated with left ventricular outflow tract gradient (r=0·35;P<0·05; and r=0·40, P=0·022, respectively) and left atrial fractional shortening (r=–0·57;P<0·001, and r=–0·35;P<0·05, respectively). Atrial but not brain natriuretic peptide plasma levels were inversely related to maximal oxygen consumption (r=–0·35;P<0·05). By stepwise multiple regression analysis, left atrial fractional shortening and left ventricular outflow tract gradient were the only predictors of atrial and brain natriuretic peptide plasma levels, respectively.
Conclusions In hypertrophic cardiomyopathy, atrial natriuretic peptide plasma levels are mainly determined by diastolic function: this explains the relationship with exercise tolerance. In contrast, brain natriuretic peptide plasma levels are mainly determined by left ventricular outflow tract gradient.
Key Words: Cardiomyopathy, hypertrophy, natriuretic peptide, diastole
f1 Correspondence: Sandro Betocchi, MD, FESC, Department of Internal Medicine, Cardiovascular and Immunological Sciences, Federico II University School of Medicine, Via S. Pansini, 5, I-80131, Naples, Italy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Jegger, R. F. da Silva, I. Lartaud, V. Gaillard, X. Jeanrenaud, M. Nasratullah, L. K. von Segesser, J. Atkinson, P. Segers, H. Tevaearai, et al. Effects of an aging vascular model on healthy and diseased hearts Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1334 - H1343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kido, N. Hasebe, Y. Ishii, and K. Kikuchi Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion of ANP, not BNP, in hypertrophic cardiomyopathy Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1064 - H1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Patel and S. R. Bailey Role of BNP in patients with severe asymptomatic aortic stenosis Eur. Heart J., November 2, 2004; 25(22): 1972 - 1973. [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Maron, V. N. Tholakanahalli, A. G. Zenovich, S. A. Casey, D. Duprez, D. M. Aeppli, and J. N. Cohn Usefulness of B-Type Natriuretic Peptide Assay in the Assessment of Symptomatic State in Hypertrophic Cardiomyopathy Circulation, March 2, 2004; 109(8): 984 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.J. Paulus Natriuretic peptides to probe haemodynamic overload in hypertrophic cardiomyopathy Eur. Heart J., August 1, 2001; 22(15): 1249 - 1251. [Abstract] [PDF]
|
|